SNGX News and Press, Soligenix Inc. From 04/30/20

Another round of stock market news has triggered momentum for several penny stocks . During a week where the bulls have started to take control, eyes are on earnings. But there are still concerns over the looming coronavirus backlash that may not even be realized yet. The eurozone’s e...

Soligenix (NASDAQ: SNGX ) jumps  23%  premarket on increased volume in reaction to additional  positive data from a Phase 3 clinical trial, FLASH , evaluating SGX301 (synthetic hypericin) in patients with early-stage cutaneous T-cell lymphoma. More news on: Soligenix, Inc....

PRINCETON, N.J. , April 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced t...

Inovio Pharmaceuticals (NASDAQ: INO ) announces the full enrollmen t of 40 healthy volunteers in a Phase 1 clinical trial of INO-4800, its COVID-19 DNA vaccine candidate. More news on: Inovio Pharmaceuticals, Inc., Moderna, Inc., Novavax, Inc., Healthcare stocks news, Stocks on the move, ...

Soligenix ( SNGX ) announced that it had achieved positive results in a phase 3 study treating patients with cutaneous T-cell lymphoma ((CTCL)). This was done using the company's drug known as SGX301. These positive results released were only the first batch for cycle 1, which only consisted o...

Edison Nation (NASDAQ: EDNT ) +169%  on over  $10M order . More news on: Edison Nation, Inc., Soligenix, Inc., Atossa Therapeutics, Inc., Stocks on the move, , Read more ...

Nano cap Soligenix (NASDAQ: SNGX ) rockets  89%  premarket on robust volume in reaction to its license deal with Boston Scientific (NYSE: BSX ) unit BTG Specialty Pharmaceuticals for exclusive global rights to CoVaccine HT, a novel vaccine adjuvant, for use in a COVID-19 vaccine....

PRINCETON, N.J. , April 16, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has executed a...

The European patent office has granted Soligenix (NASDAQ: SNGX ) the divisional patent application titled "Formulations and Methods of Treatment of Skin Conditions" (No. 2932973). More news on: Soligenix, Inc., Healthcare stocks news, Stocks on the move, Read more ...

PRINCETON, N.J. , April 6, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the E...